Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System...
December 04 2018 - 7:00AM
Endo Brain recently awarded
2018 SupplySide Editor’s Choice
Award for Brain Health
Emerald Health Therapeutics Inc. ("Emerald" or “the Company”)
(TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture,
Emerald Health Naturals (“EHN”), has received product licenses and
natural product numbers (NPNs) from Health Canada to sell its
award-winning Endo product line of endocannabinoid-supporting
nutritional products in Canada. The Endo product line has been
designed to impact stress, anxiety, restless sleep, pain and other
conditions using non-cannabis ingredients. EHN intends to launch
the Endo product line over-the-counter in Canadian natural health
product, grocery, and pharmacy stores by mid-2019.
“Our Endo product line was developed by
internationally recognized natural health product experts and is
unique in the natural healthcare marketplace. We are very excited
to be able to offer our Endo products to Canadian consumers to
support their endocannabinoid systems and improve aspects of their
health,” said Dr. Gaetano Morello, CEO of EHN. “We are leveraging
our key strategic relationships and working hard on the marketing,
manufacturing and logistical steps in order to launch the Endo line
by mid-2019.”
The Endo product line was developed by Emerald’s
joint venture partner, San Diego-based Emerald Health Bioceuticals,
Inc. (“EHB”), and its scientific advisors. Over the last year, EHB
has secured multiple distribution and sales channels in the United
States and internationally for the Endo product line, ranging from
small independent natural health product retailers to nation-wide
grocery store chains and Amazon.com. EHN, which is owned 51% by
Emerald and 49% by EHB, will have exclusive Canadian distribution
rights to the Endo products.
These cannabis-free nutritional supplements
feature PhytoCann-Complex™, a proprietary formulation designed to
support the body’s endocannabinoid system, which plays a central
role in the orchestration, maintenance, and balance of health and
well-being. The products include Endo SleepTM, Endo InflameTM, Endo
BrainTM, Endo BlissTM, and Endo CalmTM. Endo Brain was recently
awarded a prestigious 2018 SupplySide Consumer Packaged Goods
Editor’s Choice Award for Brain Health, building on its NEXTY
"Editor's Choice" Best New Supplement Award in the natural
products industry in 2017.
“We have the unique opportunity to brand Emerald
through EHN’s offering of the Endo product line through a number of
valuable sales channels that are frequently visited by cannabis
users but which cannot currently sell cannabis products,” said Dr.
Avtar Dhillon, Executive Chairman and President of Emerald. “In the
event that CBD and other non-psychoactive cannabinoid products are
allowed to be sold in these channels in the future, Emerald will be
well positioned to add its cannabinoid compounds to the Endo
product line and leverage its early marketing advantage. Emerald’s
vision is to enhance human health through cannabis science. The
creation of EHN and the launch of the Endo product line in Canada
are key steps in Emerald’s strategy to achieve this goal.”
As announced in the Company’s press release
dated November 22, 2018, the Company has obtained conditional
approval of the TSX Venture Exchange for the formation of the EHN
joint venture. The parties are in the process of finalizing
definitive documentation with respect to EHN. Formation of EHN is
conditional upon final regulatory approval and settlement of
definitive documentation.
About the
Endocannabinoid System
The endocannabinoid system (“ECS”) is a
biological system with a vital role in regulating human health and
disease. A lack of balance in the endocannabinoid system is likely
to have adverse consequences in a number of human health
conditions. The ECS is activated by endocannabinoids produced
naturally in the body, but also by cannabis or non-cannabis plant
ingredients that mimic the actions of cannabinoids produced in the
body. All products in the Endo product line contain Phyto-CannTM
Complex, which has been formulated by leading nutritional and
cannabinoid scientists with non-cannabis herbal and botanical
cannabinoids designed to favorably impact the ECS.
About Emerald Health
Therapeutics
Emerald Health Therapeutics, Inc. is a Canadian
licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint
venture in BC is completing the conversion of its 1.1 million
square feet (25 acres) greenhouse in the Lower Mainland to
cultivate cannabis and its Agro-Biotech operation in Québec is
currently operating out of its 75,000 square feet indoor cannabis
cultivation facility. Commercial production is expanding in both
facilities. In addition, Emerald has secured over 500 acres of hemp
harvest in 2018 and has contracted for approximately 1000 acres in
2019 to 2022, with the objective of extracting low-cost cannabidiol
out of its hemp harvest. Emerald’s team is highly experienced in
life sciences, product development, large-scale agri-business, and
marketing, and is focused on developing proprietary, value-added
cannabis products for medical and adult-use customers. Emerald, EHN
and EHB are all part of the Emerald Health group, which represents
a broad array of companies focused on developing pharmaceutical,
botanical, and nutraceutical products developed to provide wellness
and medical benefits by interacting with the human body’s
endocannabinoid system.
Please visit http://www.emeraldhealth.ca for
more information or contact:
Rob Hill, Chief Financial Officer(800) 757 3536
Ext. #5
Ray Lagace, Investor Relations Manager(800) 757
3536 Ext. #5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include completion of the joint venture and obtaining exclusive
Canadian distribution rights; establishing a brand; launch of the
Endo line in 2019; sales of non-cannabis products; development of
sales channels; expansion of permitted sales of cannabis;
leveraging of distribution channels; development of new products;
the benefits and effects of certain products; production capacity
of various facilities; and receipt of hemp deliveries.
Actual results may vary from forward-looking
statements. We cannot guarantee that any forward-looking statement
will materialize, and readers are cautioned not to place undue
reliance on these forward-looking statements. These forward-looking
statements involve risks and uncertainties related to, among other
things, failure to obtain necessary financing; failure to settle
final documentation; failure to obtain regulatory approvals;
results of production and sale activities; results of scientific
research; regulatory changes; changes in prices and costs of
inputs; demand for labour; demand for products; future distribution
agreements; failure of counterparties to perform contractual
obligations; as well as the risk factors described in the Company’s
annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Sep 2023 to Sep 2024